Re: Fx Plus Add-on Apk Download
Kenneth Calimlim
Customers on Dropbox Business, Business Plus, Standard, Advanced, or Enterprise get 10 years of version history with either the Extended Version History Add-On or the Data Governance Add-On. To purchase or remove either of these add-ons, do one of the following:
This service allows Shelly devices to send HTTP requests triggered by events. Events usually occur when functional device parts change their state (switch toggling, button pushes, sensor readings, etc.). There is a limit of 20 hook instances per...
I have the same issue. I attached a reed sensor with the addon plus to the shelly plus 2pm. I get the correct reed inside the shelly app but the addon sensor does not appear in HA.
Is it not supported yet or does it have to be activated somewhere.
hello, anyone added the Shelly Plus Add-On to homeassistant as digital input? I can control the input via the shelly web interface but I can not find the entity in homeassistant. I gent entity unavailable.
Groups Plus is a premium LearnDash add-on that modifies LearnDash Groups Hierarchy to create Organizations. Using WooCommerce, you can create and sell entire Organizations like you would a course and allow your customers to purchase individual course seats within their Organization. Or create a private Organization and enroll your customers on the back end.
With Groups Plus, your customers will have front-end management of their own Organization. Users can enroll and manage their Team Leaders and Team members, access reporting, grading, and more on the front end.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Purpose: PLUS investigated the efficacy and safety of mirabegron add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying lower urinary tract symptoms attributable to benign prostatic hyperplasia.
Materials and methods: In this phase 4 study a 4-week 0.4 mg tamsulosin run-in period was followed by a 12-week, randomized, double-blind, treatment period in which patients initially received 25 mg mirabegron or placebo add-on therapy. At 4 weeks doses were titrated to 50 mg mirabegron or placebo equivalent. Efficacy end points were changes from baseline to end of treatment in mean number of micturitions per day (primary), mean volume voided per micturition, number of urgency episodes per day, total urgency and frequency score, and total International Prostate Symptom Score (secondary). Safety assessments included treatment emergent adverse events, and post-void residual volume, and maximum urinary flow measurements.
Results: Of the 676 men most were 65 years old or older (380, 56.2%). Tamsulosin plus mirabegron was statistically superior to tamsulosin plus placebo in reducing the mean number of micturitions per day (-2.00 vs -1.62; adjusted difference -0.39; 95% CI -0.76, -0.02). Statistically superior results were noted for tamsulosin plus mirabegron in mean volume voided per micturition, urgency episodes per day, and total urgency and frequency score (not International Prostate Symptom Score). Higher overall treatment emergent adverse event rates were observed with tamsulosin plus placebo, although higher rates of drug related treatment emergent adverse events were noted with tamsulosin plus mirabegron. Urinary retention rates were higher in the tamsulosin plus mirabegron group. Post-void residual volume and maximum urinary flow results were not clinically meaningful.
Objective: This study compared the efficacy and safety of dual add-on of saxagliptin plus dapagliflozin versus saxagliptin and dapagliflozin added on alone in patients with type 2 diabetes poorly controlled with metformin.
Conclusions: In this first report of adding a well-tolerated combination of saxagliptin plus dapagliflozin to background metformin therapy in patients poorly controlled with metformin, greater improvements in glycemic control were obtained with triple therapy by the dual addition of saxagliptin and dapagliflozin than dual therapy with the addition of saxagliptin or dapagliflozin alone.
Objective: The objective of this study was to assess the efficacy and safety of triple therapy with saxagliptin add-on versus placebo add-on to dapagliflozin plus metformin in adults with type 2 diabetes.
Conclusions: Triple therapy with the addition of saxagliptin to dapagliflozin plus metformin was well tolerated and produced significant improvements in HbA1c in patients with type 2 diabetes inadequately controlled with dapagliflozin plus metformin.
Empagliflozin is a potent and selective inhibitor of SGLT2 (10). In phase II trials in patients with type 2 diabetes, a 12-week treatment with empagliflozin as monotherapy or as add-on to metformin resulted in reductions in HbA1c, weight, and blood pressure and was well tolerated (11,12). These effects were shown to be sustained for up to 90 weeks (13).
The aim of this study (EMPA-REG METSU) was to evaluate the efficacy, safety, and tolerability of empagliflozin (10 and 25 mg once daily) versus placebo over 24 weeks as add-on therapy to metformin plus sulfonylurea in patients with type 2 diabetes with inadequate glycemic control. In addition, the efficacy and safety of empagliflozin 25 mg was investigated in poorly controlled patients with HbA1c >10% in an open-label treatment arm.
This was a randomized, placebo-controlled, double-blind phase III study conducted from July 2010 to February 2012 in 148 centers in 12 countries (Canada, China, France, Germany, India, Korea, Mexico, Slovakia, Slovenia, Taiwan, Turkey, and the U.S.). The clinical trial protocol was approved by the institutional review boards and independent ethics committees and competent authorities of the participating centers, and the trial complied with the Declaration of Helsinki, in accordance with the International Conference on Harmonization Harmonized Tripartite Guideline for Good Clinical Practice. The trial is registered with clinicaltrials.gov (NCT01159600). All patients provided written informed consent.
Exclusion criteria included uncontrolled hyperglycemia (glucose level >13.3 mmol/L) after an overnight fast, confirmed by a second measurement), acute coronary syndrome, stroke or transient ischemic attack within 3 months prior to consent, indication of liver disease, impaired kidney function (estimated glomerular filtration rate [eGFR]
The primary end point was the change from baseline in HbA1c at week 24. Key secondary end points were change from baseline to week 24 in body weight and mean daily glucose (MDG) using an 8-point blood glucose profile.
Efficacy analysis was performed on the full analysis set (FAS), which included all randomized patients treated with one or more doses of study drug who had a baseline HbA1c value. Two-hour PPG was analyzed in the MTT set (patients in the FAS with valid baseline and one or more on-treatment MTT measurements). Safety and lipid parameters were analyzed in the treated set (patients treated with one or more doses of study drug).
Values observed after a patient started rescue medication were set to missing. The last observation carried forward (LOCF) approach was used to impute missing continuous efficacy data. MDG was also analyzed based on observed cases (OCs). Categorical efficacy variables were analyzed using noncompleters considered failure imputation. LOCF-IR imputation (i.e., LOCF without setting values after rescue therapy to missing) was used for analysis of lipid parameters. Analyses of efficacy end points in the open-label set were based on OC.
Treatment differences versus placebo in primary and key secondary end points were tested using a hierarchical testing approach for each dose at a significance level of 2.5% (two sided) to maintain the overall type I error at 5%. All other exploratory tests were two sided at a 5% level (no multiplicity adjustment). Safety analyses and analyses of efficacy end points in the open-label group were descriptive.
Reductions in FPG (Supplementary Fig. 1B and C) and 2-h PPG (Supplementary Fig. 1D) were significantly greater in the empagliflozin 10 and 25 mg groups than in the placebo group at week 24 (Supplementary Table 1). Further data on the effect of empagliflozin and placebo on these end points are given in Supplementary Section 2.
In total, 33 patients (5.0%) in the randomized groups received rescue therapy. More patients received rescue therapy in the placebo group (26 patients [11.6%]) than in the randomized empagliflozin groups (5 patients [2.2%] on 10 mg, 2 patients [0.9%] on 25 mg). Of the seven patients who required rescue medication while receiving empagliflozin, five patients received a thiazolidinedione (four patients on empagliflozin 10 mg and one patient on empagliflozin 25 mg) and two patients received an α-glucosidase inhibitor (one patient on each dose).
In the open-label group, confirmed hypoglycemic events were reported for seven patients (6.9%). Events consistent with UTI were reported for three patients (3.0%), and events consistent with genital infection were reported for two patients (2.0%).
The current study was undertaken to establish the efficacy and safety of empagliflozin 10 and 25 mg once daily for 24 weeks in patients with type 2 diabetes who had inadequate glycemic control on metformin and sulfonylurea. Both doses led to clinically meaningful improvements in glycemic control, body weight, and SBP (but not DBP) with a good tolerability and safety profile.
7fc3f7cf58